Literature DB >> 29326347

Limited-stage DLBCL: it's patient selection.

Daniel O Persky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29326347      PMCID： PMC5757692          DOI： 10.1182/blood-2017-11-813915

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  The limits of limited stage lymphoma.

Authors:  Thomas P Miller
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

2.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Evelyn Kuhnt; Lorenz Trümper; Anders Osterborg; Marek Trneny; Lois Shepherd; Devinder S Gill; Jan Walewski; Ruth Pettengell; Ulrich Jaeger; Pier-Luigi Zinzani; Ofer Shpilberg; Stein Kvaloy; Peter de Nully Brown; Rolf Stahel; Noel Milpied; Armando López-Guillermo; Viola Poeschel; Sandra Grass; Markus Loeffler; Niels Murawski
Journal:  Lancet Oncol       Date:  2011-09-21       Impact factor: 41.316

3.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Authors:  Craig H Moskowitz; Heiko Schöder; Julie Teruya-Feldstein; Camelia Sima; Alexia Iasonos; Carol S Portlock; David Straus; Ariela Noy; Maria L Palomba; Owen A O'Connor; Steven Horwitz; Sarah A Weaver; Jessica L Meikle; Daniel A Filippa; James F Caravelli; Paul A Hamlin; Andrew D Zelenetz
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

4.  Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

Authors:  Christian Récher; Bertrand Coiffier; Corinne Haioun; Thierry Jo Molina; Christophe Fermé; Olivier Casasnovas; Catherine Thiéblemont; André Bosly; Guy Laurent; Franck Morschhauser; Hervé Ghesquières; Fabrice Jardin; Serge Bologna; Christophe Fruchart; Bernadette Corront; Jean Gabarre; Christophe Bonnet; Maud Janvier; Danielle Canioni; Jean-Philippe Jais; Gilles Salles; Hervé Tilly
Journal:  Lancet       Date:  2011-11-26       Impact factor: 79.321

Review 5.  Chemotherapy alone for localized diffuse large B-cell lymphoma.

Authors:  Laurie H Sehn
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

6.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

Authors:  Daniel O Persky; Joseph M Unger; Catherine M Spier; Baldassarre Stea; Michael LeBlanc; Matthew J McCarty; Lisa M Rimsza; Richard I Fisher; Thomas P Miller
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

8.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

Authors:  T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher
Journal:  N Engl J Med       Date:  1998-07-02       Impact factor: 91.245

9.  Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Authors:  Deborah M Stephens; Hongli Li; Michael L LeBlanc; Soham D Puvvada; Daniel Persky; Jonathan W Friedberg; Sonali M Smith
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

10.  R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Authors:  Thierry Lamy; Gandhi Damaj; Pierre Soubeyran; Emmanuel Gyan; Guillaume Cartron; Krimo Bouabdallah; Rémy Gressin; Jérôme Cornillon; Anne Banos; Katell Le Du; Mohamed Benchalal; Marie-Pierre Moles; Steven Le Gouill; Joel Fleury; Pascal Godmer; Hervé Maisonneuve; Eric Deconinck; Roch Houot; Kamel Laribi; Jean Pierre Marolleau; Olivier Tournilhac; Bernard Branger; Anne Devillers; Jean Philippe Vuillez; Thierry Fest; Philippe Colombat; Valérie Costes; Vanessa Szablewski; Marie C Béné; Vincent Delwail
Journal:  Blood       Date:  2017-10-23       Impact factor: 25.476
  10 in total
  2 in total

1.  Patient Survival With and Without Radiation Therapy for Early-Stage Diffuse Large B-Cell Lymphoma in the Era of PET and Rituximab.

Authors:  Christopher McLaughlin; Anthony Ricco; Raj Singh; Nitai Mukhopadhyay; Nevena Skoro; Selamawit Girma; Xiaoyan Deng; Shiyu Song
Journal:  Adv Radiat Oncol       Date:  2022-02-28

2.  Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.

Authors:  Martin D Berger; Sven Trelle; Annina E Büchi; Sabrina Jegerlehner; Codruta Ionescu; Thierry Lamy de la Chapelle; Urban Novak
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.